Astonea Labs Ltd
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
- Market Cap ₹ 154 Cr.
- Current Price ₹ 147
- High / Low ₹ 151 / 135
- Stock P/E 40.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 16.4 %
- ROE 37.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 152 to 116 days.
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 30.04 | 66.89 | 80.16 | |
| 24.21 | 59.75 | 68.21 | |
| Operating Profit | 5.83 | 7.14 | 11.95 |
| OPM % | 19.41% | 10.67% | 14.91% |
| 0.12 | 0.21 | 0.10 | |
| Interest | 1.58 | 2.34 | 2.97 |
| Depreciation | 3.79 | 3.93 | 3.97 |
| Profit before tax | 0.58 | 1.08 | 5.11 |
| Tax % | 56.90% | 38.89% | 25.44% |
| 0.25 | 0.67 | 3.81 | |
| EPS in Rs | 0.62 | 1.68 | 5.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 546% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 38% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 7.60 |
| Reserves | 3.49 | 4.16 | 4.38 |
| 29.53 | 35.99 | 42.39 | |
| 15.89 | 20.13 | 26.52 | |
| Total Liabilities | 52.91 | 64.28 | 80.89 |
| 21.39 | 20.75 | 21.93 | |
| CWIP | 0.00 | 0.00 | 2.10 |
| Investments | 0.00 | 0.00 | 0.00 |
| 31.52 | 43.53 | 56.86 | |
| Total Assets | 52.91 | 64.28 | 80.89 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -4.93 | -1.05 | 4.05 | |
| -3.31 | -3.08 | -7.18 | |
| 8.17 | 4.14 | 3.45 | |
| Net Cash Flow | -0.07 | 0.01 | 0.32 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 234.63 | 104.11 | 115.79 |
| Inventory Days | 136.35 | 121.40 | 160.81 |
| Days Payable | 273.08 | 128.11 | 148.90 |
| Cash Conversion Cycle | 97.89 | 97.41 | 127.70 |
| Working Capital Days | 191.49 | 125.56 | 129.77 |
| ROCE % | 8.01% | 16.40% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Jun
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 16 Jun
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
11 Jun - Company Secretary Avneet Kaur resigns effective 4 July 2025 to pursue other career opportunity.
- Listing of Equity Shares of Astonea Labs Ltd 3 Jun
Annual reports
No data available.
Business Verticals[1]
a) Own brands: ** Its own brand include "Glow Up" (cosmetics) and "Regero" (pharmaceuticals).
b) Contract Manufacturing**: It also engages in contract manufacturing for domestic and international clients, serving markets like the USA, Bolivia, Guatemala, Botswana, Iraq, and Yemen.